OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration fo
Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HB
Myogen has announced that the United States Food and Drug Administration has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH). Ambrisentan is cu
Aventis began to ship its influenza vaccine (Fluzone(R), Influenza Virus Vaccine) today, meeting the company's goal to provide Fluzone vaccine to customers to allow health-care providers to plan succe
Watson Pharmaceuticals announced today that it has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for nicotine polacrilex gum, mint f
CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient
Almost a third of heart failure patients face an increased risk of death because they do not receive an angiotensin-converting enzyme (ACE) inhibitor, according to a report in today's rapid access issue of Circulation: Journal of the
Michigan Attorney General Mike Cox announced today a settlement with pharmaceutical manufacturer Schering Plough over its underpayment of Medicaid Drug Rebates on the antihistamine drug Claritin, n
Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary,
Pfizer has announced that the U.S. Food and Drug Administration has approved its cholesterol-lowering therapy Lipitor? (atorvastatin calcium) for the prevention of cardiovascular disease by reducing he
The mistakes apparently occurred because the trade names Reminyl and Amaryl are somewhat similar.
Amaryl reduces blood sugar, a potentially serious effect in those who are not diabetic and do not have higher-than-normal blood sugar levels. Two individuals who mistakenly received Amaryl died.
Reminyl and Amaryl do not look alike. While Reminyl tablets are round, Amaryl has an unusual oblong shape that looks like two circles pushed together, with a flattened surface where they join. Each Amaryl tablet is stamped "Amaryl." Each Reminyl tablet is stamped with a capital "G" for galantamine and a 4, 8, or 12 noting the strength in milligrams.
The shapes and colors of the different strengths of Reminyl and Amaryl are shown in the pictures above.
The potential confusion does not apply to any of the other approved Alzheimer drugs: tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon) or memantine (Namenda).
If you have any questions about whether you are taking the right medication, please contact your doctor as soon as possible.
http://www.alz.org